Updating results

58 results for dermatology Sort: Relevance | Date

Melanoma: assessment and management (NG14)

Evidence-based recommendations on assessing and managing melanoma (a type of skin cancer).

NICE guideline Published July 2015

Atopic eczema in under 12s: diagnosis and management (CG57)

Evidence-based recommendations on diagnosing and managing atopic eczema (dermatitis) in children under 12

Clinical guideline Published December 2007

Psoriasis

Everything NICE has said on psoriasis in an interactive flowchart

NICE Pathway Published October 2011 Last updated June 2018

Eczema

Everything NICE has said on managing atopic eczema in children up to 12 years, and treating eczema in people aged 13 years and over in an interactive flowchart

NICE Pathway Published August 2012 Last updated July 2018

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Food allergy in under 19s

Everything NICE has said on diagnosing and assessing food allergy in children and young people in primary care and community settings in an interactive flowchart

NICE Pathway Published December 2011 Last updated October 2017

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Tildrakizumab for treating moderate to severe plaque psoriasis [ID1060]

In development [GID-TA10191] Expected publication date: 17 April 2019

Technology appraisal guidance In development

Certolizumab pegol for treating moderate to severe plaque psoriasis [ID1232]

In development [GID-TA10240] Expected publication date: 17 April 2019

Technology appraisal guidance In development

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

ESNM14: Actinic keratosis: ingenol mebutate gel

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

ES10: Hyperhidrosis: oxybutynin

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

ESUOM31: Chronic urticaria: off-label doses of cetirizine

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer

Medical technologies guidance Published July 2011

ESNM43: Facial erythema of rosacea: brimonidine tartrate gel

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

ESNM68: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

ESUOM29: Difficult-to-treat scabies: oral ivermectin

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Spondyloarthritis in over 16s: diagnosis and management (NG65)

Evidence-based recommendations on diagnosing and managing spondyloarthritis that is suspected or confirmed in over 16s

NICE guideline Published February 2017 Last updated June 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367]

In development [GID-TA10304] Expected publication date: 03 July 2019

Technology appraisal guidance In development

ESUOM47: Infantile haemangioma: topical timolol

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

ESUOM16: Hyperhidrosis: oral glycopyrronium bromide

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Haematological cancers: improving outcomes (NG47)

Evidence-based recommendations on integrated diagnostics reporting and improving services, staffing and care for people with haematological cancer

NICE guideline Published May 2016

Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

Evidence-based recommendations on treating obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) for adults, young people and children

Clinical guideline Published November 2005

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

Committee A members

His clinical interests are paediatric HIV and paediatric dermatology. He is also the clinical lead for paediatrics.

Published March 2018

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Spondyloarthritis (QS170)

Evidence-based statements to deliver quality improvements in diagnosing and managing spondyloarthritis in adults aged 16 and over

Quality standard Published June 2018

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Sunlight exposure: risks and benefits

Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

NICE Pathway Published February 2016 Last updated June 2017

ESNM66: External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

Diagnostics guidance Published November 2015

Spondyloarthritis

Everything NICE has said on diagnosing and managing spondyloarthritis in people aged 16 and over in an interactive flowchart

NICE Pathway Published February 2017 Last updated June 2018

Melanoma

Everything NICE has said assessing and managing melanoma in an interactive flowchart

NICE Pathway Published July 2015 Last updated May 2018

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017